เอกสารอ้างอิง
[1] DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: a pathophysiologic approach. 10th ed. Columbus (OH): McGraw-Hill; 2017.
[2] Brunton LL, Chabner BA, Knollmann BC, editors. Goodman and Gilman’s pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill Medical; 2017
[3] Gandhi J, Weissbart SJ, Smith NL, Kaplan SA, Dagur G, Zumbo A, Joshi G, Khan SA. The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia. Transl Androl Urol. 2017 Apr;6(2):295-304.
[4] Rosen, Raymond & Carson, Culley. (2005). Sexual Dysfunction and Lower Urinary Tract Symptoms (LUTS) Associated with Benign Prostatic Hyperplasia (BPH). European urology. 47. 824-37. 10.1016/j.eururo.2004.12.013.
[5] Bhasin S, Basson R. Sexual Dysfunction in Men and Women : Williams Textbook of Endocrinology. 14th ed. Elsevier; 2020. https://www.clinicalkey.com/#!/content/book/3-s2.0-B9780323555968000206?scrollTo=%23hl0001965. Accessed January 7, 2020.
[6] Miller, J., Carson, C.C. Alpha blockers and ejaculatory function: A state of the art review. Curr sex health rep 4, 141–144 (2007)
[7] Van Dijk MM, de la Rosette JJ, Michel MC. Effects of alpha(1)-adrenoceptor antagonists on male sexual function. Drugs. 2006;66(3):287-301. Review. PubMedPMID: 16526818.